These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

783 related articles for article (PubMed ID: 30696472)

  • 1. Novel stereotactic body radiation therapy (SBRT)-based partial tumor irradiation targeting hypoxic segment of bulky tumors (SBRT-PATHY): improvement of the radiotherapy outcome by exploiting the bystander and abscopal effects.
    Tubin S; Popper HH; Brcic L
    Radiat Oncol; 2019 Jan; 14(1):21. PubMed ID: 30696472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mono-institutional phase 2 study of innovative Stereotactic Body RadioTherapy targeting PArtial Tumor HYpoxic (SBRT-PATHY) clonogenic cells in unresectable bulky non-small cell lung cancer: profound non-targeted effects by sparing peri-tumoral immune microenvironment.
    Tubin S; Khan MK; Salerno G; Mourad WF; Yan W; Jeremic B
    Radiat Oncol; 2019 Nov; 14(1):212. PubMed ID: 31771654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time-synchronized immune-guided SBRT partial bulky tumor irradiation targeting hypoxic segment while sparing the peritumoral immune microenvironment.
    Tubin S; Ashdown M; Jeremic B
    Radiat Oncol; 2019 Dec; 14(1):220. PubMed ID: 31801549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shifting the Immune-Suppressive to Predominant Immune-Stimulatory Radiation Effects by SBRT-PArtial Tumor Irradiation Targeting HYpoxic Segment (SBRT-PATHY).
    Tubin S; Gupta S; Grusch M; Popper HH; Brcic L; Ashdown ML; Khleif SN; Peter-Vörösmarty B; Hyden M; Negrini S; Fossati P; Hug E
    Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33375357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hunting for abscopal and bystander effects: clinical exploitation of non-targeted effects induced by partial high-single-dose irradiation of the hypoxic tumour segment in oligometastatic patients.
    Tubin S; Raunik W
    Acta Oncol; 2017 Oct; 56(10):1333-1339. PubMed ID: 28686524
    [No Abstract]   [Full Text] [Related]  

  • 6. Stereotactic Body Radiotherapy (SBRT) for Spinal Metastases: Who Will Benefit the Most from SBRT?
    Park HJ; Kim HJ; Won JH; Lee SC; Chang AR
    Technol Cancer Res Treat; 2015 Apr; 14(2):159-67. PubMed ID: 24502552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re-irradiation stereotactic body radiotherapy for spinal metastases: a multi-institutional outcome analysis.
    Hashmi A; Guckenberger M; Kersh R; Gerszten PC; Mantel F; Grills IS; Flickinger JC; Shin JH; Fahim DK; Winey B; Oh K; John Cho BC; Létourneau D; Sheehan J; Sahgal A
    J Neurosurg Spine; 2016 Nov; 25(5):646-653. PubMed ID: 27341054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility study of stereotactic body radiotherapy for peripheral lung tumors with a maximum dose of 100 Gy in five fractions and a heterogeneous dose distribution in the planning target volume.
    Takeda A; Oku Y; Sanuki N; Eriguchi T; Aoki Y; Enomoto T; Kaneko T; Nishimura S; Kunieda E
    J Radiat Res; 2014 Sep; 55(5):988-95. PubMed ID: 24833770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiosurgery and fractionated stereotactic body radiotherapy for patients with lung oligometastases.
    Kalinauskaite GG; Tinhofer II; Kufeld MM; Kluge AA; Grün AA; Budach VV; Senger CC; Stromberger CC
    BMC Cancer; 2020 May; 20(1):404. PubMed ID: 32393261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients.
    König L; Häfner MF; Katayama S; Koerber SA; Tonndorf-Martini E; Bernhardt D; von Nettelbladt B; Weykamp F; Hoegen P; Klüter S; Susko MS; Debus J; Hörner-Rieber J
    Radiat Oncol; 2020 Feb; 15(1):30. PubMed ID: 32019553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postoperative re-irradiation using stereotactic body radiotherapy for metastatic epidural spinal cord compression.
    Ito K; Nihei K; Shimizuguchi T; Ogawa H; Furuya T; Sugita S; Hozumi T; ; Karasawa K
    J Neurosurg Spine; 2018 Sep; 29(3):332-338. PubMed ID: 29905524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".
    Rieber J; Streblow J; Uhlmann L; Flentje M; Duma M; Ernst I; Blanck O; Wittig A; Boda-Heggemann J; Krempien R; Lohaus F; Klass ND; Eble MJ; Imhoff D; Kahl H; Petersen C; Gerum S; Henkenberens C; Adebahr S; Hass P; Schrade E; Wendt TG; Hildebrandt G; Andratschke N; Sterzing F; Guckenberger M
    Lung Cancer; 2016 Jul; 97():51-8. PubMed ID: 27237028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of stereotactic body radiotherapy (SBRT) treatment of multiple synchronous and recurrent lung nodules.
    Owen D; Olivier KR; Mayo CS; Miller RC; Nelson K; Bauer H; Brown PD; Park SS; Ma DJ; Garces YI
    Radiat Oncol; 2015 Feb; 10():43. PubMed ID: 25889747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-institutional outcome-analysis of low-dose stereotactic body radiation therapy (SBRT) of adrenal gland metastases.
    Voglhuber T; Kessel KA; Oechsner M; Vogel MME; Gschwend JE; Combs SE
    BMC Cancer; 2020 Jun; 20(1):536. PubMed ID: 32513136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic body radiotherapy of central lung malignancies using a simultaneous integrated protection approach : A prospective observational study.
    Mazzola R; Ruggieri R; Figlia V; Rigo M; Giaj Levra N; Ricchetti F; Nicosia L; Corradini S; Alongi F
    Strahlenther Onkol; 2019 Aug; 195(8):719-724. PubMed ID: 30689026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.
    Pokhrel D; Sood S; Badkul R; Jiang H; McClinton C; Lominska C; Kumar P; Wang F
    J Appl Clin Med Phys; 2016 May; 17(3):277-293. PubMed ID: 27167284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linac-based stereotactic body radiation therapy for unresectable locally advanced pancreatic cancer: risk-adapted dose prescription and image-guided delivery.
    Mazzola R; Fersino S; Aiello D; Gregucci F; Tebano U; Corradini S; Di Paola G; Cirillo M; Tondulli L; Ruffo G; Ruggieri R; Alongi F
    Strahlenther Onkol; 2018 Sep; 194(9):835-842. PubMed ID: 29696321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypofractionated stereotactic body radiotherapy in spinal metastasis - with or without epidural extension.
    Anand AK; Venkadamanickam G; Punnakal AU; Walia BS; Kumar A; Bansal AK; Singh HM
    Clin Oncol (R Coll Radiol); 2015 Jun; 27(6):345-52. PubMed ID: 25726363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic body radiotherapy (SBRT) in recurrent or oligometastatic pancreatic cancer : A toxicity review of simultaneous integrated protection (SIP) versus conventional SBRT.
    Gkika E; Adebahr S; Kirste S; Schimek-Jasch T; Wiehle R; Claus R; Wittel U; Nestle U; Baltas D; Grosu AL; Brunner TB
    Strahlenther Onkol; 2017 Jun; 193(6):433-443. PubMed ID: 28138949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment.
    Fuller DB; Wurzer J; Shirazi R; Bridge SS; Law J; Mardirossian G
    Pract Radiat Oncol; 2015; 5(6):e615-23. PubMed ID: 26059509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.